Immuno-Oncology 360° Launches Newsletter to Raise a Wide Variety of Voices Fighting Cancer

Share Article

The Conference Forum’s Immuno-Oncology 360° group launched their first IO360° newsletter dedicated to addressing advancements of clinical, scientific and business developments in immuno-oncology by highlighting a wide variety of perspectives from all areas of the IO space. The IO360° newsletter will feature extraordinary individuals who contribute to this science and motivate and inspire the wider IO community.

“By adding the IO360° newsletter to our IO360° portfolio, we are able to provide timely insights and ongoing support throughout the year for the Immuno-Oncology community,” said Kate Woda, Conference Director of Immuno-Oncology 360° Group.

The Conference Forum’s Immuno-Oncology 360° group launched their first IO360° newsletter dedicated to addressing advancements of clinical, scientific and business developments in immuno-oncology by highlighting a wide variety of perspectives from all areas of the IO space. The IO360° newsletter will feature extraordinary individuals who contribute to this science and motivate and inspire the wider IO community.

“By adding the IO360° newsletter to our IO360° portfolio, we are able to provide timely insights and ongoing support throughout the year for the Immuno-Oncology community,” said Kate Woda, Conference Director of Immuno-Oncology 360° Group.

The interviews will capture scientist, clinician, operations, patient and investor perspectives, and cover topics ranging from cancer vaccines, checkpoint blockade therapy, the tumor microenvironment, bispecific antibodies, combination therapies, R&D strategies, the clinical trial experience, clinical operations, manufacturing, data management, cell and gene therapy, immune monitoring, CAR-T therapy to solid tumors, the future of IO, personal experiences and more.

The launch interview issue of IO360° features cell therapy pioneer and serial entrepreneur Dr Arie Belldegrun, Executive Chairman and Co-Founder, Allogene Therapeutics and Co-Founder and Senior Managing Director, Vida Ventures.

The inaugural interview issue of IO360° also features Dr Lisa Butterfield, VP, R&D, Parker Institute for Cancer Immunotherapy, Dr Dimitris Skokos, Senior Director, Cancer Immunology Research, Regeneron, Adriana Comprelli, Therapeutic Area Head, Clinical Operations Strategy, BMS, Steve Hamilton, Cancer Veteran, and Dr John Connolly, CSO, Parker Institute of Cancer Immunotherapy.

Immuno-Oncology 360° group presents the IO Combinations 360° and Immuno-Oncology 360° conferences and Immuno-Oncology themed podcasts.

About the Conference Forum:

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.

They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.

Learn more about The Conference Forum at theconferenceforum.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

BreAnna Bugbee
Visit website